The AQST stock forecast scenario for Q2 2024 aligns with analyst models projecting a 15% YoY revenue increase, driven by enhanced licensing deals. Traders see $3.20 as the next test level. We can see that Aquestive Therapeutics does have institutional investors; and they hold a good portion of the company's stock. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Aquestive Therapeutics' earnings history below. Of course, the future is what really matters. Sales of royalty-based products, inclusive of Sympazan ® (clobazam) Oral Film for the treatment of seizures associated with Lennox-Gastaut Syndrome in patients two years of age and older, and Azstarys ® (serdexmethylphenidate and dexmethylphenidate) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients six years of age and older, continued to contribute to the Company's revenue in the first quarter of 2025.
